Amgen (AMGN) Receivables (2009 - 2026)

Amgen's Receivables history runs 18 years deep, the most recent figure standing at $9.1 billion for Q1 2026.

• In Q1 2026, Receivables rose 12.37% year-over-year to $9.1 billion; the TTM figure through Mar 2026 stood at $9.1 billion (up 12.37% YoY), while the FY2025 annual figure was $9.6 billion, up 37.11% from the prior year.
• Receivables was $9.1 billion for Q1 2026 at Amgen, down from $9.6 billion in the prior quarter.
• In the past five years, Receivables ranged from a high of $9.6 billion in Q4 2025 to a low of $5.1 billion in Q1 2022.
• Historically, Receivables has averaged $7.0 billion across 5 years, with a median of $6.9 billion in 2024.
• The sharpest annual moves came in 2024 and 2025: Receivables retreated 10.17% in 2024, then soared 37.11% in 2025.
• A 5-year view of Receivables shows it stood at $5.7 billion in 2022, then jumped by 36.51% to $7.8 billion in 2023, then retreated by 10.17% to $7.0 billion in 2024, then jumped by 37.11% to $9.6 billion in 2025, then declined by 4.51% to $9.1 billion in 2026.
• The last three Receivables figures came in at $9.1 billion (Q1 2026), $9.6 billion (Q4 2025), and $8.5 billion (Q3 2025), per Business Quant data.